The aim of the study was to select, from a panel of candidate European human immunodeficiency virus type 1 (HIV-1) clade B primary virus isolates, one isolate based on replication properties in chimpanzee peripheral blood mononuclear cells (PBMC). Secondly, to evaluate the in vivo kinetics of primary infection of the selected isolate at two different doses in two mature, outbred chimpanzees (Pan troglodytes). Four different low passage, human PBMC-cultured ‘primary’ HIV-1 isolates with European clade B consensus sequence were compared for their ability to replicate in vitro in chimpanzee versus human PBMC. The isolate which yielded the highest titre and most vigorous cytopathic effect in chimpanzee PBMC was evaluated for coreceptor usage and chosen for evaluation in vivo. Only the HIV-1Han2 isolate replicated in chimpanzee PBMC in vitro at detectable levels. This isolate was demonstrated to utilize CCR4, CCR5 and CXCR4 co-receptors and could be inhibited by β-chemokines. Infection of chimpanzees was demonstrated by viral RNAand DNAPCR analysis, both in plasma as well as in PBMC and lymph node cells as early as 3 weeks after inoculation. Antibodies developed within 6 weeks and continued to increase to a maximum titre of approximately 12800, thereafter remaining in this range over the follow-up period of 2 years. Compared to cell line-adapted HIV-1 isolates there were slight but no dramatic differences in the kinetics of infection of chimpanzees with this particular primary isolate.
BermanP. W., GroopmanJ. E., GregoryT., ClaphamP. R., WeissR. A., FerrianiR., RiddleL., ShimasakiC., LucasC., LaskyL. A.1988; Human immunodeficiency virus type 1 challenge of chimpanzees immunized with recombinant envelope glycoprotein gp120. Proceedings of the National Academy of Sciences, USA 85:5200–5204
BogersW. M., DubbesR., ten HaaftP., NiphuisH., Cheng-MayerC., Stahl-HennigC., HunsmannG., KuwataT., HayamiM., JonesS., RanjbarS., AlmondN., StottJ., RosenwirthB., HeeneyJ. L.1997a; Comparison of in vitro and in vivo infectivity of different clade B HIV-1 envelope chimeric simian/human immunodeficiency viruses in Macaca mulatta. Virology 236:110–117
BogersW. M., KoornstraW. H., DubbesR. H., NaraP., BuijsL., HeeneyJ. L.1997b; Potent HIV-1 inhibiting soluble factor from chimpanzee peripheral blood cells. In Research in HIV and Cytokines pp. 211–215GuenounouM. Edited by Paris: Inserm;
GirardM., KienyM. P., PinterA., Barre-SinoussiF., NaraP., KolbeH., KusumiK., ChaputA., ReinhartT., MuchmoreE., FultzP.1991; Immunization of chimpanzees confers protection against challenge with human immunodeficiency virus. Proceedings of the National Academy of Sciences, USA 88:542–546
GirardM., MeignierB., Barre-SinoussiF., KienyM. P., MatthewsT., MuchmoreE., NaraP. L., WeiQ., RimskyL., WeinholdK., FultzP.1995; Vaccine-induced protection of chimpanzees against infection by a heterologous human immunodeficiency virus type 1. Journal of Virology 69:6239–6248
GroeninkM., FouchierR. A., de GoedeR. E., de WolfF., GrutersR. A., CuypersH. T., HuismanH. G., TersmetteM.1991; Phenotypic heterogeneity in a panel of infectious molecular human immunodeficiency virus type 1 clones derived from a single individual. Journal of Virology 65:1968–1975
HeeneyJ. L., van ElsC., de VriesP., ten HaaftP., OttingN., KoornstraW., BoesJ., DubbesR., NiphuisH., DingsM., CranageM., NorleyS., JonkerM., BontropR. E., OsterhausA.1994; Major histocompatibility complex class I-associated vaccine protection from simian immunodeficiency virus-infected peripheral blood cells. Journal of Experimental Medicine 180:769–774
KozakS. L., PlattE. J., MadaniN., FerroF.JrPedenK., KabatD.1997; CD4, CXCR-4, and CCR-5 dependencies for infections by primary patient and laboratory-adapted isolates of human immuno-deficiency virus type 1. Journal of Virology 71:873–882
MurthyK. K., CobbE. K., el AmadZ., OrtegaH., HsuehF. C., SatterfieldW., LeeD. R., KalishM. L., HaigwoodN. L., KennedyR. C., SteimerK. S., SchultzA., LevyJ. A.1996; Titration of a vaccine stock preparation of human immunodeficiency virus type 1 SF2 in cultured lymphocytes and in chimpanzees. AIDS Research and Human Retroviruses 12:1341–1348
MyersG., KorberB., Wain-HobsonS., JeangK.-T., HendersonL. E., PavlakisG. N.1994Human retroviruses and AIDS database Los Alamos, NM: Los Alamos National Laboratory;
SauermannU., SchneiderJ., MousJ., BrunckhorstU., SchedelI., JentschK. D., HunsmannG.1990; Molecular cloning and characterization of a German HIV-1 isolate. AIDS Research and Human Retroviruses 6:813–823
SchuitemakerH., KootstraN. A., GroeninkM., De GoedeR. E., MiedemaF., TersmetteM.1992; Differential tropism of clinical HIV-1 isolates for primary monocytes and promonocytic cell lines. AIDS Research and Human Retroviruses 8:1679–1682
ShibataR., HogganM. D., BrosciusC., EnglundG., TheodoreT. S., Buckler-WhiteA., ArthurL. O., IsraelZ., SchultzA., LaneH. C.1995; Isolation and characterization of a syncytium-inducing, macrophage/T-cell line-tropic human immunodeficiency virus type 1 isolate that readily infects chimpanzee cells in vitro and in vivo. Journal of Virology 69:4453–4462
SimmonsG., WilkinsonD., ReevesJ. D., DittmarM. T., BeddowsS., WeberJ., CarnegieG., DesselbergerU., GrayP. W., WeissR. A., ClaphamP. R.1996; Primary, syncytium-inducing human immuno-deficiency virus type 1 isolates are dual-tropic and most can use either Lestr or CCR5 as coreceptors for virus entry. Journal of Virology 70:8355–8360
ten HaaftP. J. F., CornelissenM., GoudsmitJ., KoornstraW., DubbesR., NiphuisH., PeetersM., ThiriartC., BruckC., HeeneyJ. L.1995; Virus load in chimpanzees infected with human immunodeficiency virus type 1 : effect of pre-exposure vaccination. Journal of General Virology 76:1015–1020